32,000 Shares in Biohaven Ltd. (NYSE:BHVN) Bought by Bryce Point Capital LLC

Bryce Point Capital LLC purchased a new stake in Biohaven Ltd. (NYSE:BHVN) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 32,000 shares of the company’s stock, valued at approximately $1,195,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Spire Wealth Management acquired a new stake in Biohaven in the 4th quarter valued at about $56,000. Amalgamated Bank lifted its position in shares of Biohaven by 21.9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock valued at $109,000 after buying an additional 527 shares during the last quarter. US Bancorp DE lifted its position in shares of Biohaven by 36.7% in the fourth quarter. US Bancorp DE now owns 2,971 shares of the company’s stock valued at $111,000 after buying an additional 798 shares during the last quarter. KBC Group NV boosted its stake in shares of Biohaven by 50.1% during the 4th quarter. KBC Group NV now owns 3,377 shares of the company’s stock worth $126,000 after acquiring an additional 1,127 shares during the period. Finally, Diversified Trust Co increased its holdings in shares of Biohaven by 16.6% during the 4th quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock worth $209,000 after acquiring an additional 795 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on shares of Biohaven and gave the stock a “buy” rating in a report on Thursday, March 20th. JPMorgan Chase & Co. lowered their price target on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Finally, Morgan Stanley decreased their target price on Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Biohaven currently has a consensus rating of “Buy” and a consensus price target of $62.77.

Biohaven Stock Performance

NYSE:BHVN opened at $23.67 on Thursday. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -2.53 and a beta of 1.27. Biohaven Ltd. has a fifty-two week low of $21.47 and a fifty-two week high of $55.72. The stock has a fifty day moving average price of $34.21 and a 200-day moving average price of $41.09.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Research analysts predict that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Insider Buying and Selling

In other Biohaven news, Director John W. Childs acquired 32,700 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the transaction, the director now directly owns 2,320,571 shares in the company, valued at $70,707,798.37. This represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 16.00% of the stock is currently owned by company insiders.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.